Volume 4, Issue 3 (Summer 2023)                   J Vessel Circ 2023, 4(3): 123-132 | Back to browse issues page

Ethics code: IR.MUQ.REC.1399.057
Clinical trials code: IRCT20160118026097N5

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Adeli S H, Parham M, Asghari A, Tabaraii R, Shajari R, Abadpoor Z, et al et al . Therapeutic Potential of Plasma Exchange, Systemic Corticosteroids, and, Interferon for Severe COVID-19: A Non-randomized Controlled Trial. J Vessel Circ 2023; 4 (3) :123-132
URL: http://jvessels.muq.ac.ir/article-1-271-en.html
Therapeutic Potential of Plasma Exchange, Systemic Corticosteroids, and, Interferon for Severe COVID-19: A Non-randomized Controlled Trial
Seyed Hasan Adeli1 , Mahmoud Parham1 , Akram Asghari1 , Reihane Tabaraii1 , Rasoul Shajari1 , Zahra Abadpoor1 , Sara Afshari2 , Narges Kalhor2 , Ali Ebrazeh3 , Amir Jabbari4 , Saeede Jafari5 , Khosro Dehghan1 , Hossein Fazli Sarvestani1 , Mansoureh Shakeri6 , Sajjad Ahmadpour7 , Jamshid Vafaeimanesh * 8
1- Department of Internal Medicine, School of Medicine, Qom University of Medical, Qom, Iran.
2- Student Research Committee, Qom University of Medical Sciences, Qom, Iran.
3- Department of Public Health, School of Health, Qom University of Medical Sciences, Qom, Iran.
4- Gastroenterology and Hepatology Disease Research Center, Qom University of Medical Sciences, Qom, Iran.
5- Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
6- Clinical Research of Development Unit, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom Iran.
7- Patient Safety Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran.
8- Gastroenterology and Hepatology Disease Research Center, Qom University of Medical Sciences, Qom, Iran. & Clinical Research of Development Unit, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom Iran.
Abstract:   (531 Views)
Background and Aim: Since 2019, the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) virus has spread systematically, causing extensive immune responses and significant damage to other organs. This non-randomized, open-labeled, clinical trial was conducted to evaluate the effect of therapeutic plasma exchange (TPE) on critically ill coronavirus disease 2019 (COVID-19) patients.
Materials and Methods: This single-center clinical trial was performed at Shahid Beheshti Hospital affiliated with the Qom University of Medical Sciences, from March to June 2020. A total of 60 patients with serious or life-threatening COVID-19 infection were included in the study. Patients in the intervention group (30 patients) received systemic corticosteroids and interferon and TPE were performed for them.
Results: Of the 60 patients studied, 48% died, while about 52% were discharged. Mortality was significantly lower in the intervention group than in the control group (20% vs 77%, respectively). The severity of the disease was significantly lower in the intervention group than in the control group (20% vs 77%, respectively), although the median days of hospitalization and ICU admission were higher in the intervention group than in the control group. No side effects were observed in the intervention group during the first 72 hours after TPE.
Conclusion: TPE can provide a longer lifeline and a lower mortality rate in critically ill COVID-19 patients. Therefore, we recommend that TPE, systemic corticosteroids, and interferon, along with other standard treatments, be used as part of the treatment protocol for critically ill COVID-19 patients.
Keywords: COVID-19, Plasma exchange, Corticosteroids, Interferon, Hospitalization, Mortality rate
Full-Text [PDF 907 kb]   (101 Downloads) |   |   Full-Text (HTML)  (84 Views)  
Type of Study: Research | Subject: vascular nephrology
Received: 2023/12/21 | Accepted: 2024/03/4 | Published: 2024/02/29
References
1. Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis. 2020; 39(6):1011-9. [DOI:10.1007/s10096-020-03874-z] [PMID] [DOI:10.1007/s10096-020-03874-z]
2. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): Current status and future perspective. Int J Antimicrob Agents. 2020; 55(5):105951. [DOI:10.1016/j.ijantimicag.2020.105951] [PMID] [DOI:10.1016/j.ijantimicag.2020.105951]
3. McFee RB. SARS 2 human coronavirus (COVID -19, SARS CoV2). Dis Mon. 2020; 66(9):101063. [DOI: 10.1016/j.disamonth.2020.101063] [PMID] [DOI:10.1016/j.disamonth.2020.101063]
4. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020; 92(6):568-76. [DOI:10.1002/jmv.25748] [PMID] [DOI:10.1002/jmv.25748]
5. Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as a potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020; 38(1):10-8. [DOI:10.12932/AP-200220-0773] [DOI:10.12932/AP-200220-0773]
6. Sokunbi TO, Omojuyigbe JO. Need for sustainable health policies toward curbing future pandemics in Africa. Ann Med Surg. 2022; 82. [DOI:10.1016/j.amsu.2022.104506] [DOI:10.1016/j.amsu.2022.104506]
7. Yurdaisik I. Effectiveness of computed tomography in the diagnosis of novel coronavirus-2019. Cureus. 2020; 12(5):e8134.[DOI:10.7759/cureus.8134] [DOI:10.7759/cureus.8134]
8. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. 2020; 395(10229):1014-5.[DOI:10.1016/S0140-6736(20)30633-4] [PMID] [DOI:10.1016/S0140-6736(20)30633-4]
9. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the CytokineStorm'in COVID-19. J Infect. 2020; 80(6):607-13. [DOI:10.1016/j.jinf.2020.03.037] [PMID] [DOI:10.1016/j.jinf.2020.03.037]
10. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-81. [DOI:10.1016/S2213-2600(20)30079-5] [PMID] [DOI:10.1016/S2213-2600(20)30079-5]
11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 395(10229):1054-62. [DOI:10.1016/S0140-6736(20)30566-3] [PMID] [DOI:10.1016/S0140-6736(20)30566-3]
12. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020; 395(10223):507-513. [DOI:10.1016/S0140-6736(20)30211-7] [PMID] [DOI:10.1016/S0140-6736(20)30211-7]
13. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-9. [DOI:10.1001/jama.2020.1585] [PMID] [DOI:10.1001/jama.2020.1585]
14. Schönrich G, Raftery MJ, Samstag Y. Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression. Adv Biol Regul. 2020; 77:100741. [DOI:10.1016/j.jbior.2020.100741] [PMID] [DOI:10.1016/j.jbior.2020.100741]
15. Zehra Z, Luthra M, Siddiqui SM, Shamsi A, Gaur NA, Islam A. Coronavirus versus the existence of humans on the earth: A computational and biophysical approach. Int J Biol Macromol. 2020; 161:271-81. [DOI:10.1016/j.ijbiomac.2020.06.007] [PMID] [DOI:10.1016/j.ijbiomac.2020.06.007]
16. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Yet al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. [DOI:10.1016/S0140-6736(20)30183-5] [PMID] [DOI:10.1016/S0140-6736(20)30183-5]
17. Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020; 53:38-42. [DOI:10.1016/j.cytogfr.2020.04.002] [PMID] [DOI:10.1016/j.cytogfr.2020.04.002]
18. Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: An argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care. 2020; 24(1):128. [DOI:10.1186/s13054-020-2836-4] [PMID] [DOI:10.1186/s13054-020-2836-4]
19. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180(7):934-43.[DOI:10.1001/jamainternmed.2020.0994] [PMID] [DOI:10.1001/jamainternmed.2020.0994]
20. Mihai C, Dobrota R, Schröder M, Garaiman A, Jordan S, Becker MO, et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis. 2020; 79(5):668-9. [DOI:10.1136/annrheumdis-2020-217442] [PMID] [DOI:10.1136/annrheumdis-2020-217442]
21. Adeli SH, Asghari A, Tabarraii R, Shajari R, Afshari S, Kalhor N, et al. Using therapeutic plasma exchange as a rescue therapy in CoVID-19 patients: A case series. Pol Arch Intern Med. 2020; 130(5):455-8. [DOI:10.20452/pamw.15340] [PMID] [DOI:10.20452/pamw.15340]
22. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of clinical criteria for sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):762-74.[DOI:10.1001/jama.2016.0288] [PMID] [DOI:10.1001/jama.2016.0288]
23. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033-4. [DOI:10.1016/S0140-6736(20)30628-0] [PMID] [DOI:10.1016/S0140-6736(20)30628-0]
24. Turgutkaya A, Yavasoglu I, Bolaman Z. Application of plasmapheresis for covid‐19 patients. Ther Apher Dial. 2021; 25(2):248-9. [DOI:10.1111/1744-9987.13536] [PMID] [DOI:10.1111/1744-9987.13536]
25. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020; 71(16):2027-34.[DOI:10.1093/cid/ciaa344] [PMID] [DOI:10.1093/cid/ciaa344]
26. Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of immunoglobulin g and igm antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(16):2255-8. [DOI:10.1093/cid/ciaa489] [PMID] [DOI:10.1093/cid/ciaa489]
27. Zhang B, Zhou X, Zhu C, Song Y, Feng F, Qiu Y, et al. Immune phenotyping based on the neutrophil-to-lymphocyte ratio and igg level predicts disease severity and outcome for patients with covid-19. Front Mol Biosci. 2020; 7:157. [DOI:10.3389/fmolb.2020.00157] [PMID] [DOI:10.3389/fmolb.2020.00157]
28. Yeh JH, Chen WH, Chiu HC, Bai CH. Clearance studies during subsequent sessions of double filtration plasmapheresis. Artif Organs. 2006; 30(2):111-4. [DOI:10.1111/j.1525-1594.2006.00189.x] [PMID] [DOI:10.1111/j.1525-1594.2006.00189.x]
29. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(5):1023-6. [DOI:10.1111/jth.14810] [PMID] [DOI:10.1111/jth.14810]
30. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: A two-centre descriptive study. Lancet Infect Dis. 2020; 20(10):1135-40. [DOI:10.1016/S1473-3099(20)30434-5] [PMID] [DOI:10.1016/S1473-3099(20)30434-5]
31. Stahl K, Schmidt JJ, Seeliger B, Schmidt BMW, Welte T, Haller H, et al. Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock. Crit Care. 2020; 24(1):71. [DOI:10.1186/s13054-020-2799-5] [PMID] [DOI:10.1186/s13054-020-2799-5]
32. Alexander V, Zachariah U, Goel A, Kandasamy S, Chacko B, Punitha JV, et al. Low-volume plasma exchange and low-dose steroid to treat secondary hemophagocytic lymphohistiocytosis: A potential treatment for severe COVID-19?. Curr Med Issues. 2020; 18(2):77-82. [DOI:10.4103/cmi.cmi_48_20] [DOI:10.4103/cmi.cmi_48_20]
33. Li Y, Liu S, Zhang S, Ju Q, Zhang S, Yang Y, et al. Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies. Transfusion and Apheresis Science. 2020; 59(5):102839. [DOI:10.1016/j.transci.2020.102839] [DOI:10.1016/j.transci.2020.102839]
34. Ishikawa T, Abe S, Kojima Y, Sano T, Iwanaga A, Seki KI, et al. Prediction of sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin. Exp Ther Med. 2015; 9(5):1646-50. [DOI:10.3892/etm.2015.2340] [PMID] [DOI:10.3892/etm.2015.2340]
35. Tsang K, Zhong NS. SARS: Pharmacotherapy. Respirology. 2003; 8 Suppl:S25-30. [PMID] [DOI:10.1046/j.1440-1843.2003.00525.x]
36. Koch B, Schult-Dietrich P, Büttner S, Dilmaghani B, Lohmann D, Baer PC, et al. Lectin affinity plasmapheresis for Middle East respiratory syndrome-coronavirus and Marburg virus glycoprotein elimination. Blood Purif. 2018; 46(2):126-33. [DOI:10.1159/000487224] [PMID] [DOI:10.1159/000487224]
37. Liu X, Zhang Y, Xu X, Du W, Su K, Zhu C, et al. Evaluation of plasma exchange and continuous veno‐venous hemofiltration for the treatment of severe avian influenza a (H7N9): A cohort study. Ther Apher Dial. 2015; 19(2):178-84. [DOI:10.1111/1744-9987.12240] [PMID] [DOI:10.1111/1744-9987.12240]
38. Khamis F, Al-Zakwani I, Al Hashmi S, Al Dowaiki S, Al Bahrani M, Pandak N, et al. Therapeutic plasma exchange in adults with severe COVID-19 Infection. Int J Infect Dis. 2020; 99:214-8. [DOI:10.1016/j.ijid.2020.06.064] [PMID] [DOI:10.1016/j.ijid.2020.06.064]
39. Faqihi F, Alharthy A, Alodat M, Kutsogiannis DJ, Brindley PG, Karakitsos D. Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study. J Crit Care. 2020; 60:328-33. [PMID] [DOI:10.1016/j.jcrc.2020.07.001]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Vessels and Circulation

Designed & Developed by : Yektaweb